LeMaitre Vascular (NASDAQ:LMAT) Rating Increased to Outperform at Barrington Research

Key Points

• LeMaitre Vascular received an upgrade from Barrington Research, moving from a "market perform" rating to an "outperform" rating, with a target price of $95.00.
• The company reported $0.60 earnings per share for the last quarter, surpassing estimates and reflecting a 15.0% increase in revenue compared to the previous year.
• CEO George W. LeMaitre sold 4,399 shares, decreasing his ownership slightly while 84.64% of the stock is held by institutional investors and hedge funds.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) was upgraded by equities research analysts at Barrington Research from a "market perform" rating to an "outperform" rating in a research note issued to investors on Wednesday, MarketBeat reports. The firm presently has a $95.00 target price on the medical instruments supplier's stock. Barrington Research's price target suggests a potential upside of 2.95% from the stock's current price. Barrington Research also issued estimates for LeMaitre Vascular's Q3 2025 earnings at $0.57 EPS, Q4 2025 earnings at $0.60 EPS, FY2025 earnings at $2.25 EPS, Q2 2026 earnings at $0.69 EPS, Q3 2026 earnings at $0.63 EPS, Q4 2026 earnings at $0.65 EPS, FY2026 earnings at $2.58 EPS and FY2027 earnings at $2.94 EPS.

LeMaitre Vascular Trading Down 2.1%

Shares of LMAT stock traded down $1.98 during trading hours on Wednesday, reaching $92.28. 149,596 shares of the stock were exchanged, compared to its average volume of 146,164. LeMaitre Vascular has a 12-month low of $71.42 and a 12-month high of $109.58. The company has a current ratio of 13.96, a quick ratio of 13.83 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.09 billion, a price-to-earnings ratio of 44.80, a price-to-earnings-growth ratio of 2.37 and a beta of 0.79. The company's 50-day moving average price is $83.35 and its 200-day moving average price is $86.57.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.03. The firm had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. The firm's quarterly revenue was up 15.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.52 earnings per share. As a group, equities analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Insider Buying and Selling at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 100,000 shares of the company's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total value of $9,351,000.00. Following the sale, the chief executive officer directly owned 1,727,003 shares of the company's stock, valued at $161,492,050.53. This represents a 5.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 200,000 shares of company stock valued at $17,907,857 over the last quarter. 9.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Several hedge funds have recently modified their holdings of LMAT. Summitry LLC purchased a new stake in shares of LeMaitre Vascular during the second quarter worth approximately $221,000. Cetera Investment Advisers grew its stake in shares of LeMaitre Vascular by 44.6% in the 2nd quarter. Cetera Investment Advisers now owns 12,319 shares of the medical instruments supplier's stock valued at $1,023,000 after buying an additional 3,797 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in LeMaitre Vascular by 7.8% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 5,279 shares of the medical instruments supplier's stock worth $438,000 after acquiring an additional 383 shares during the last quarter. Police & Firemen s Retirement System of New Jersey increased its position in shares of LeMaitre Vascular by 6.6% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 4,712 shares of the medical instruments supplier's stock worth $391,000 after purchasing an additional 293 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of LeMaitre Vascular by 3.0% during the second quarter. Geode Capital Management LLC now owns 519,792 shares of the medical instruments supplier's stock valued at $43,174,000 after acquiring an additional 15,036 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.